Search PubMed⌕ Search

Biomedical subjects

F Ferrara

Publications and source records attributed to F Ferrara.

At least 91 records · Page 5Linked to original sources
PubMed1989

Miokamycin and leukocyte activity in man.

The effects of miokamycin on the immune system were studied in healthy volunteers by means of the following assays: phagocytosis, intracellular killing and natural killer activity. The tests were performed before, 2 and 6 h after oral administration of 600 mg of miokamycin. The findings suggest that miokamycin stimulates phagocytosis and intracellular killing. These effects could be clearly shown 2 h after drug intake and disappeared at the 6th hour. On the contrary, the natural killer activity was not significantly stimulated by miokamycin.

Adult↗
PubMed1989

Cortical and medullary kidney tissue levels of cefonicid in human beings.

Cefonicid concentration has been determined microbiologically in cortical and medullary tissue in 30 patient undergoing surgery because of neoplastic disease localized within the kidney. Each subject received 1 g of cefonicid intramuscularly in a single administration. The patients were divided into six groups, from which samples of blood and tissue were collected 2, 4, 6, 8, 12, 24 h respectively after treatment with the drug. The mean peak serum levels appeared at the second hour (74.96 +/- 8.14 mcg/ml) and the decay shows a monoexponential behaviour, reaching a minimum value of 5.4 +/- 2.33 mcg/ml at the 24th hour. In the cortical tissue of the kidney the peak levels appeared at the fourth hour (26.22 +/- 8.87 mcg/g), while at the 24th hour levels were about 3.08 +/- 0.81 mcg/g. A very similar behaviour could also be observed in the medullary tissue of the kidney with peak levels at the fourth hour (25.82 +/- 10.06 mcg/g) and levels of 3.48 +/- 0.85 mcg/g at the 24th hour. A delay in the decay of tissue levels in comparison with the decay of blood levels could be observed from the eighth hour.

Adult↗
PubMed1988

Xibornol: multiple dose pharmacokinetics and diffusion in lung, tonsillar tissue and laryngeal mucosa.

In ten patients with severe chronic bronchitis and in a further 23 with planned resection of lung, tonsils or larynx, 500 mg doses, single or multiple, of xibornol (6-isobronyl-3, 4-xylenol) were administered for an antibacterial effect. The pharmacokinetics and diffusion of the drug in the tissues were studied. A high diffusion and distribution value of xibornol was observed, with levels in the tissues constantly higher than that in the serum. The concentrations reached within the respiratory tract were adequate for their antibacterial effect.

Administration, Oral↗
PubMed1987

Effects of lincomycin on the immune system.

The effects of lincomycin on the immune system were studied on patients suffering from chronic bronchitis by means of phagocytosis, chemotaxis and natural-killer tests. The tests were performed before and 2, 4, 8, 12 and 24 h after administration of 600 mg lincomycin i.m. in a single dose. The results indicate that lincomycin stimulates phagocytosis, expressed as enhanced superoxide production (O2-), chemotaxis and the activity of natural killer cells, measured on the basis of their ability to perform a lysis on the K562 tumoral target labelled with 51Cr. The stimulating effects on chemotaxis appear already 2 h after the administration of the drug, while the same effect on phagocytosis and natural-killer activity occurs after 4 h. The maximal stimulating activity on all three parameters can be shown at 8 h and disappears at 24 h.

Adult↗
PubMed1986

Evaluation of the immunostimulating activity of erythromycin in man.

The effects of erythromycin on the immune system have been studied in healthy volunteers and patients suffering from chronic bronchopneumonial diseases, by means of the following assays: phagocytosis, natural killer activity and superoxide anion production. The tests were performed before and after oral administration of 1 g of erythromycin. The findings suggest that erythromycin enhances phagocytosis by means of increasing ingestion of microorganisms, superoxide anion (O2-) production as well as natural killer activity. Under the experimental conditions described these effects appear 4-6 h after drug intake and reach their maximum around the 8th hour.

Adult↗
PubMed1986

Differentiated distribution of norfloxacin in the medullary-cortical part of the kidney in man.

Norfloxacin administered orally in a single dose of 400 mg, rapidly reaches high levels in the renal tissues, and provides an effective therapeutic action against sensitive pathogen germs. Twelve hours after administration, the drug is still detectable in the renal tissue; particularly, it was evidenced a positive tropism in the medullary part of renal parenchyma, where they were found norfloxacin levels far higher than those of cortical parts.

Female↗
PubMed1985

Position of ceftazidime in respiratory diseases.

Twenty patients (10 males and 10 females), ranging in age from 53 to 81 years, were treated with ceftazidime, 2-3 g/day i.m., for 12 to 15 days. All patients were suffering from moderate to severe infections of the lower respiratory tract (6 cases of pneumonia and 14 cases of acute exacerbation of chronic bronchitis). In addition, almost all patients presented severe local and general predisposing factors (three patients with lung cancer, two with bronchiectasis and 14 with respiratory insufficiency). The aetiological agents responsible for the infections were mainly Gram-negative bacteria (6 Klebsiella pneumoniae, 4 Haemophilus influenzae, 4 Pseudomonas aeruginosa and 3 Proteus strains). The clinical and microbiological results of the treatment were good. With the exception of one case of maculopapular rash, none of the patients complained of adverse reactions and no toxic effects were observed.

Aged↗
PubMed1985

Physiopathological rationale and clinical aims of the use of a combination of cefuroxime and N-acetylcysteine in pneumology.

The trial population consisted of 50 patients suffering from acute exacerbations of chronic bronchial disease processes. Forty patients were treated with an extempore combination of cefuroxime and N-acetylcysteine at the doses of 2 g and 600 mg/day respectively in two i.m. administrations. The other 10 patients were treated with N-acetylcysteine alone at the same dose. Respiratory tract clinical and instrumental parameters were investigated, and bacteriological tests were performed on sputum samples before and after treatment. Tolerance of the treatment was assessed on the basis of measurement of blood-chemistry parameters.

Acetylcysteine↗
PubMed1984

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias.

In this study, the effects of 5-aza-2'-deoxycytidine on differentiation of human leukemic cells in primary suspension culture are reported for the first time. Morphological and functional differentiation was induced in cells from two acute monoblastic leukemias and two of three acute myeloid leukemias following repeated exposures to 1 mumol/L 5-aza-2'-deoxycytidine. The observation that nontoxic concentrations of the drug are able to induce the in vitro differentiation of both monoblastic and myeloblastic leukemic cells into mature elements may encourage the exploitation of the differentiating properties of 5-aza-2'-deoxycytidine in chemotherapy protocols for acute non-lymphoblastic leukemias.

Azacitidine↗